Archive for November, 2017

$FCEL and Toyota $TM Announce Renewable Transportation Fuel Project

  • FuelCell Energy to install fuel cell power plant at Port of Long Beach, California to generate renewable hydrogen and power
  • Toyota to purchase renewable hydrogen for fuel cell vehicle refueling
  • Power generated by the fuel cells will be sold to the grid under State of California Bioenergy Market Adjustment Tariff (BioMAT) program

DANBURY, Conn., Nov. 30, 2017 — FuelCell Energy, Inc.  (Nasdaq:FCEL), a global leader in delivering clean, innovative and affordable fuel cell solutions for the supply, recovery and storage of energy, today announced the execution of a hydrogen and power off-take agreement with Toyota, outlining an innovative collaboration  in which Toyota will purchase renewable hydrogen for vehicle fueling generated on-site from a multi-megawatt SureSourceTM fuel cell  power plant located at the Port of Long Beach in California.  FuelCell Energy will install and operate a fuel cell power plant that will be configured for hydrogen production to generate and supply 100 percent renewable hydrogen for Toyota’s fuel cell electric vehicles (FCEV’s) and its heavy duty fuel cell Class 8 proof of concept truck.  The fuel cell plant will simultaneously generate renewable power to be supplied to the grid under the California Bioenergy Market Adjustment Tariff (BioMAT) program.  This fuel cell solution meets Toyota’s fueling needs affordably and sustainably, while supporting the advancement of California’s hydrogen fueling infrastructure and adhering to the state’s mandate for utilizing low-carbon and renewable sources.

“Fueling our Proof of concept Semi-Truck, as well as our Mirai fuel cell electric vehicles with 100 percent renewable hydrogen from this stationary fuel cell system is a major accomplishment, and a key step in building a sustainable hydrogen ecosystem to help power Port operations,” said Doug Murtha, Group Vice President – Strategic Planning, Toyota. “Toyota is a company dedicated to advancing sustainability, and this project supports our ongoing efforts to both eliminate carbon emissions and accelerate the development and adoption of emission-free fuel cell electric vehicles.”

“This is an innovative and replicable global model for building an affordable hydrogen infrastructure to generate renewable transportation fuel that facilitates the wider adoption of fuel cell electric cars, trucks and buses,” said Chip Bottone, Chief Executive Officer, FuelCell Energy, Inc. “We are pleased to provide Toyota with a flexible project structure that meets their needs both sustainably and economically.”

FuelCell Energy’s distributed hydrogen solution co-produces hydrogen and clean power from methane based fuels such as renewable biogas.  The methane is reformed to hydrogen using water and heat produced by the fuel cell, resulting in clean hydrogen production without water consumption.  In January 2016 the California Air Resources Board (CARB) certified a prospective pathway for hydrogen production with this technology fueled by biogas.  CARB’s team performed a complete Life Cycle Analysis (LCA) on the system and determined that it has a negative carbon intensity, as the power and hydrogen generation process is carbon-neutral due to the use of renewable biogas and the fuel cell waste heat is used to feed the internal reformation reactions.

The multi-megawatt SureSource HydrogenTM plant will be located at the Port of Long Beach, generating renewable hydrogen to fuel Toyota’s Mirai vehicles as they arrive at the Port and its heavy-duty fuel cell Class 8 proof of concept truck.

Fuel cells utilize an electro-chemical process to convert a fuel source into electricity and heat in a highly efficient process that emits virtually no pollutants as the fuel is not burned.  The combination of near-zero pollutants, modest land-use needs, and quiet operating nature of these stationary fuel cell power plants facilitates installation in urban locations where the power is used.  Customers benefit with operating cost reductions delivered in a manner that supports sustainability goals and enhances power reliability.

Cautionary Language 
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements with respect to Fuelcell’s expectations regarding energy cost savings, overall system efficiency, expectation regarding the amount of power generation and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of FuelCell and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and FuelCell undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although FuelCell believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements.  For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of FuelCell in general, see the risk disclosures in FuelCell’s filings with the Securities and Exchange Commission.

About FuelCell Energy
FuelCell Energy (NASDAQ:FCEL) delivers efficient, affordable and clean solutions for the supply, recovery and storage of energy.  We design, manufacture, undertake project development, install, operate and maintain megawatt-scale fuel cell systems, serving utilities, industrial and large municipal power users with solutions that include both utility-scale and on-site power generation, carbon capture, local hydrogen production for transportation and industry, and long duration energy storage.  With SureSource™ installations on three continents and millions of megawatt hours of ultra-clean power produced, FuelCell Energy is a global leader with environmentally responsible power solutions.  Visit us online at www.fuelcellenergy.com and follow us on Twitter.

SureSource, SureSource 1500, SureSource 3000, SureSource 4000, SureSource Recovery, SureSource Capture, SureSource Hydrogen, SureSource Storage, SureSource Service, SureSource Capital, FuelCell Energy, and FuelCell Energy logo are all trademarks of FuelCell Energy, Inc.

Contact:
FuelCell Energy, Inc.
Kurt Goddard, Vice President Investor Relations
203-830-7494
ir@fce.com

Thursday, November 30th, 2017 Uncategorized Comments Off on $FCEL and Toyota $TM Announce Renewable Transportation Fuel Project

$AKAO to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 — Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that management will be hosting investor meetings at the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel in Boston, Massachusetts.

Investors attending the conference who are interested in meeting with Achaogen management should contact their Guggenheim Securities representative.

About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company’s second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen’s plazomicin program has been funded, and its C-Scape program is funded, in part with Federal funds from the Biomedical Advanced Research and Development Authority. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.

Source: Achaogen, Inc. (NASDAQ:AKAO)

Investor and Media Contact
David Arrington
Vice President, Investor Relations and Corporate Communications
650.440.5856
darrington@achaogen.com

Thursday, November 30th, 2017 Uncategorized Comments Off on $AKAO to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference

$CYTK Phase 1 Studies of CK-2127107 Highlights Tolerability, Pharmacodynamics

Next Generation Fast Skeletal Muscle Activator Appears Promising Compared to Tirasemtiv in Studies of Healthy Volunteers

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the publication of results from three double-blind, randomized, placebo-controlled Phase 1 clinical studies that evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-2127107, an investigational next-generation fast skeletal muscle troponin activator (FSTA). The results showed that CK-2127107 increased the force generated by the tibialis anterior muscle versus placebo in response to nerve stimulation in a dose, plasma concentration, and frequency-dependent manner. Single doses of CK-2127107 were well-tolerated in healthy volunteers at doses up to 4000 mg. No serious adverse effects (SAEs) were reported and adverse effects (AEs) were all mild or moderate. Additionally, the results showed that CK-2127107 appeared more potent and produced a larger increase in force than tirasemtiv which was evaluated in a comparable study.1 The publication, titled “CK-2127107 Amplifies Skeletal Muscle Response to Nerve Activation in Humans,” is published online in Muscle & Nerve.2

“These published results reinforce CK-2127107 as a promising drug candidate with potential advantages relative to tirasemtiv that may include tolerability and potency,” said Fady I. Malik, MD, PhD, Cytokinetics’ Executive Vice President of Research & Development. “We look forward to the results from four ongoing mid-stage clinical trials of CK-2127107 anticipated in 2018.”

CY 5011 was a single ascending dose crossover clinical trial that evaluated the safety, tolerability and pharmacokinetics of single doses of CK-2127107 in 35 healthy male participants. Participants received two ascending, active doses and one placebo dose, one in each of three treatment periods. CK-2127107 was well tolerated at all dose levels ranging from 30 mg to 4000 mg. A maximum tolerated dose was not achieved. All AEs were mild or moderate, and no clinically meaningful changes from baseline were observed in the neurological examination, walk test, laboratory values, vital signs, ECG parameters or pulse oximetry. Exposure to CK-2127107 increased approximately dose proportionally.

CY 5012 was a multiple ascending dose, parallel group clinical trial that evaluated the safety, tolerability and pharmacokinetics of CK-2127107 in male and female healthy volunteers. The clinical trial enrolled 59 young (aged 18-55) and elderly (aged 65-85) participants. Three cohorts enrolled young participants and two enrolled elderly participants; four cohorts received 300 mg or 500 mg for 10 days and one cohort received 500 mg for 17 days. CK-2127107 was generally well-tolerated at all doses administered, and all AEs were mild or moderate. No other clinically meaningful changes from baseline were observed in other laboratory values, neurological examination, vital signs, or ECG parameters, and there were no clinically meaningful differences in pharmacokinetics of CK-2127107 between young and elderly participants. Steady state was achieved in elderly participants dosed with 300 mg for 10 days and young participants taking 500 mg for 17 days.

CY 5013 was a single-dose, four-period crossover clinical trial of CK-2127107 in 16 healthy male participants that evaluated the change in the force-frequency profile of the tibialis anterior muscle during transcutaneous stimulation of the deep fibular nerve and its relationship to dose and plasma concentrations of CK-2127107. Participants received placebo, 300 mg, 1000 mg and 3000 mg single doses in random order administered one week apart. Single doses were well-tolerated and all AEs were mild or moderate. CK-2127107 increased the response of the tibialis anterior muscle to neuronal input as dose and plasma concentration increased. The overall largest increase from baseline in peak force, compared to placebo, was 58.7 (10.2)% (least-squares mean [SE]) occurring at a stimulation frequency of 10 Hz. For comparison, the largest response tirasemtiv produced in a comparable study was a 24.5 (3.1)% increase in peak force at 10 Hz.1 The effect of CK-2127107 on the force-frequency relationship was also related to the stimulation frequency, being greatest at approximately the rate that motor units typically discharge during daily physical activity.

These results suggest that by directly increasing skeletal muscle force production, with maximal effects in the middle of the 5 to 15 Hz range where most normal daily human muscle activity occurs3,4, CK-2127107 may have an effect on physical performance in patients with neuromuscular and non-neuromuscular diseases in which weakness and fatigue are the result of reduced skeletal muscle force production. Furthermore, the results show that compared to the first-generation FSTA tirasemtiv, CK-2127107 may be more potent and produce larger increases in force.

About CK-2127107

CK-2127107 is an investigational next-generation FSTA arising from Cytokinetics’ skeletal muscle contractility program. CK-2127107 was derived from a different chemical structural class and was designed to have certain advantages relative to tirasemtiv. CK-2127107 appears to be more potent than tirasemtiv in preclinical models and in humans and appears better tolerated compared to tirasemtiv in comparable Phase 1 studies. CK-2127107 has demonstrated pharmacological activity that diseases associated with muscle weakness and fatigue. CK-2127107 has been the subject of five completed Phase 1 clinical trials in healthy volunteers, which evaluated the safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics of the drug candidate. CK-2127107 is the subject of an ongoing clinical development program in neuromuscular and non-neuromuscular diseases and conditions associated with muscle dysfunction and weakness, including three Phase 2 trials currently underway in patients with each of spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), or chronic obstructive pulmonary disease (COPD), as well as a Phase 1b trial in elderly subjects with limited mobility.

About Cytokinetics and Astellas Collaboration

Cytokinetics and Astellas collaborate on the research, development, and commercialization of skeletal muscle activators. The primary objective of the collaboration is to advance novel therapies for diseases and medical conditions associated with muscle impairment and weakness. Cytokinetics has licensed to Astellas exclusive rights to develop and commercialize CK-2127107 and other FSTAs in non-neuromuscular indications and certain neuromuscular indications (including SMA and ALS) and other novel mechanism skeletal muscle activators in all indications, subject to certain Cytokinetics’ development and commercialization rights; Cytokinetics may co-promote and conduct certain commercial activities in North America and Europe under agreed scenarios.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics is collaborating with Astellas Pharma Inc. (“Astellas”) to develop CK-2127107, a next-generation FSTA. CK-2127107 has been granted orphan drug designation by the FDA for the potential treatment of SMA. CK-2127107 is the subject of three ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. Astellas is also conducting a Phase 1b clinical trial of CK-2127107 in elderly adults with limited mobility. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Cytokinetics is collaborating with Amgen Inc. (“Amgen”) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Licenses held by Amgen and Astellas are subject to Cytokinetics’ specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit www.cytokinetics.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities, including our continuing review and assessment related to the results from VITALITY-ALS, our evaluation, in consultation with the FDA and other regulatory authorities of future development plans for tirasemtiv and the process and timing of anticipated future development of tirasemtiv; the design, results, significance and utility of preclinical study results; and the properties and potential benefits of CK-2127107 and Cytokinetics’ other drug candidates.  Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for CK-2127107; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

References

  1. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S,  Enoka RM, Morgans DJ, Wolff AA, Malik FI. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve. 2014 Dec;50(6):925-31.
  2. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve. 2017 Nov 18.
  3. Person RS, Kudina LP. Discharge frequency and discharge pattern of human motor units during voluntary contraction of muscle. Electroencephalography and clinical neurophysiology. 1972;32(5):471-483.
  4. Tanji J, Kato M. Firing rate of individual motor units in voluntary contraction of abductor digiti minimi muscle in man. Experimental neurology. 1973;40(3):771-783.

Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(415) 290-7757

Thursday, November 30th, 2017 Uncategorized Comments Off on $CYTK Phase 1 Studies of CK-2127107 Highlights Tolerability, Pharmacodynamics

$YGYI Subsidiary, CLR Roasters, Purchases $7.5 Million of Green Coffee Contracts for 2018

MIAMI, FL–(Nov 30, 2017) – Youngevity International (NASDAQ: YGYI), a leading omni-direct lifestyle company, today announced its wholly owned subsidiary CLR Roasters, makers of Café La Rica Espresso, “The Official Cafecito of the Miami Marlins,” has entered into a purchase contract to deliver approximately $7.5 million of green coffee for the 2018 selling season. The commitment is for Naturals coffee grown in Nicaragua.

Ernesto Aguila, President of CLR Roasters, said, “We are optimistic about the potential for growth of our green coffee distribution business in 2018. This commitment from one of our green coffee distribution partners represents a 60% increase in volume over 2017. We are optimistic that we will also experience growth from our other distribution partners for this segment in 2018.”

Dave Briskie, Youngevity’s President and CFO, said, “This new $7.5 million-dollar Green Coffee commitment represents a good start to the 2018 booking season. We experienced efficiency gains and revenue growth this year coming from our Nicaraguan-based operations. This has assisted us in strengthening our relationships with our Green Coffee Distribution partners which we anticipate will lead to stronger sales of green coffee in 2018. I am proud of our team’s efforts and contributions orchestrated by our local partners: Alain Hernandez, Marisol Silas and Ernesto Aguila, who assisted greatly in developing this business.”

About CLR Roasters

CLR Roasters (www.clrroasters.com) was established in 2001 and is a wholly-owned subsidiary of Youngevity International. CLR Roasters produces coffees under its own boutique brands as well as manufactures a variety of private labels through various tiers of distribution. Industries served include grocery, retail, wholesalers, hospitality, cruise lines, wellness facilities, office coffee service, and convenience store distribution. It also produces a unique line of coffees with health benefits under the JavaFit® brand.

About Youngevity International, Inc.

Youngevity International, Inc. (NASDAQ: YGYI), is a leading omni-direct lifestyle company — offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, Youngevity offers proven products from the six top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. The Company was formed during the summer 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For investor information, please visit YGYI.com. For general information on products and services, please visit us at youngevity.com. Keep up with our activities by liking us on Facebook and following us on Twitter.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “encouraged” and similar expressions. The forward-looking statements contained in this press release include statements regarding the potential for growth of our green coffee distribution business in 2018, the anticipated stronger sales of green coffee in 2018 and the growth from our other distribution partners for this segment in 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that that could cause actual results to differ materially from current expectations include, among others, our ability to increase sales of green coffee in 2018, and the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2016 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Investor Relations:
Chuck Harbey
PCG Advisory Group
charbey@pcgadvisory.com
646 863 7997

Thursday, November 30th, 2017 Uncategorized Comments Off on $YGYI Subsidiary, CLR Roasters, Purchases $7.5 Million of Green Coffee Contracts for 2018

$IMMR Appointment of Board Chair, Carl Schlachte, as Interim CEO

SAN JOSE, Calif.

Immersion Corp. (Nasdaq: IMMR), the leading developer and licensor of touch feedback technology, today announced that at the request of the Board of Directors, Vic Viegas has agreed to resign as Chief Executive Officer and as a director.

Carl Schlachte, currently Chairman of the Board, has been unanimously elected by the Board as Interim CEO. Mr. Schlachte joined the Immersion Board in 2011 and was elected as Chairman in 2012. He currently serves as Chairman and CEO of Ventiva, Inc., which designs and develops thermal management technologies for consumer applications in mobile computing, power electronics and LED lighting. He will continue to serve as Chairman of the Board of Immersion during his tenure as Interim CEO.

“After a thorough review of our business and strategy, the Board has decided to pursue new leadership for the company. We are commencing a search for a permanent CEO, and until the completion of this process, I am honored that the Board has put its trust in me to serve as Interim CEO,” said Mr. Schlachte. “On behalf of the Board, I want to thank Vic for his years of dedicated service to Immersion. We wish him the very best.”

“Immersion’s recently announced licensing agreements continue to demonstrate that the technology and IP developed by our employees have significant value around the world,” Mr. Schlachte said. “As a long-time Board member, I am a deep believer in the value of our haptic technology solutions, as well as in our innovative culture and strong intellectual property portfolio. I am excited about the opportunities in front of Immersion.”

About Immersion

Immersion is the leading innovator of touch feedback technology, also known as haptics. The company provides technology solutions for creating immersive and realistic experiences that enhance digital interactions by engaging users’ sense of touch. With more than 2,600 issued or pending patents, Immersion’s technology has been adopted in more than 3 billion digital devices, and provides haptics in mobile, automotive, advertising, gaming, medical and consumer electronics products. Immersion is headquartered in San Jose, California with offices worldwide. Learn more at www.immersion.com.

Forward Looking Statements

This press release contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Immersion Corporation and its consolidated subsidiaries to differ materially from those expressed or implied by such forward-looking statements. All statements, other than the statements of historical fact, are statements that may be deemed forward-looking statements, including, but not limited to, statements regarding the company’s leadership transition, the benefits of Immersion’s technology and its business strategy.

Immersion’s actual results might differ materially from those stated or implied by such forward-looking statements due to risks and uncertainties associated with Immersion’s business, which include, but are not limited to: unanticipated difficulties and challenges encountered in product development efforts by Immersion and its licensees; adverse outcomes in any future intellectual property-related litigation and the costs related thereto; the effects of the current macroeconomic climate; delay in or failure to achieve adoption of or commercial demand for Immersion’s products or third party products incorporating Immersion’s technologies; and a delay in or failure to achieve the acceptance of touch feedback as a critical user experience. Many of these risks and uncertainties are beyond the control of Immersion.

For a more detailed discussion of these factors, and other factors that could cause actual results to vary materially, interested parties should review the risk factors listed in Immersion’s most current Form 10-K, and Form 10-Q, both of which are on file with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release reflect Immersion’s beliefs and predictions as of the date of this release. Immersion disclaims any obligation to update these forward-looking statements as a result of financial, business, or any other developments occurring after the date of this release.

Immersion and the Immersion logo are trademarks of Immersion Corporation in the United States and other countries. All other trademarks are the property of their respective owners.

(IMMR – C)

 

Immersion Corp.
Nancy Erba, +1 408-350-8850
nerba@immersion.com
or
The Blueshirt Group
Jennifer Jarman, +1 415-217-5866
jennifer@blueshirtgroup.com

Thursday, November 30th, 2017 Uncategorized Comments Off on $IMMR Appointment of Board Chair, Carl Schlachte, as Interim CEO

$MYSZ Will Participate in the International CES Tradeshow

AIRPORT CITY, Israel, November 30, 2017 —

My Size, Inc. (the “Company” or “My Size”) (NASDAQ: MYSZ; TASE: MYSZ), the developer and creator of smartphone measurement applications, announced today that it will participate in the international CES innovation tradeshow in Las Vegas on January 9-12, 2018, where it will unveil a technological breakthrough.

In addition, the Company will present its 3 flagship products – SizeUp, TrueSize and BoxSizeID – all based on algorithms that are capable of calculating and recording dimensions through various methods, aiming to simplify matters for customers and improve retailer and supplier revenues:

  • SizeUp Measurement from the Air application, officially launched at the previous CES tradeshow on January 5, 2017, is a smart “measuring tape” that enables users to perform immediate and accurate Smartphone measurements of smooth or rough surfaces. This product is intended mainly for the home improvement and the do-it-yourself, or DIY, markets. Since its launch, the application that is currently available on 33 types of Smartphones has over 530,000 downloads. To view – Click here.
  • TrueSize (Real Size – white Labe product customized for TRUCCO) enables consumers to match the sizes of their outfits with the correct size of an item selected from a retailer’s website. To view – Click here.
  • BoxSizeId is an intuitive application for measuring parcels, which is intended to improve and manage the work process for shipping companies. The application enables users to easily measure the size of their parcel and accurately calculate the shipping price before delivery. To view a short film about the application – Click here.

“Over the past year since the prior CES tradeshow, we have improved our technology, launched additional products using the measurement algorithm and extended the variety of devices with which the application can be used”, said Ronen Luzon, My Size CEO. “I am pleased to say that we will also be presenting new developments and innovations at the tradeshow this year.  We are glad to lead the way in measurement technologies and are proud to play an integral part in the global change introduced by the e-commerce revolution.”

The annual CES tradeshow held in Las Vegas is considered among the major platforms for introducing innovation and advanced technology. More than 3,900 companies present at the tradeshow, including, but not limited to, manufacturers, developers and technology, software and hardware specialists.  The tradeshow expects to attract over 170,000 participants from approximately 150 countries. For more information about the trade show – Click here.

About My Size, Inc.
My Size, Inc. (TASE: MYSZ) (NASDAQ: MYSZ) has developed a unique measurement technology based on sophisticated algorithms and cutting-edge technology with broad applications including the apparel, e-commerce, DIY, shipping and parcel delivery industries. This proprietary technology is driven by several algorithms which are able to calculate and record measurements in a variety of novel ways. To learn more about My Size, please visit our website http://www.mysizeid.com. Follow us on Facebook, LinkedIn and Twitter .

Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements.  All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved.  Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections.  Known material factors that could cause actual results to differ materially from those in the forward-looking statements include: an active trading market for our common stock may not develop on NASDAQ; the trading price for our common stock may fluctuate significantly; and the Company will continue to be a “controlled company,” as defined under NASDAQ rules, and the interests of our controlling stockholder may differ from those of our public stockholders.  Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission.  Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Press Contact:
Eran Yoels
Rimon, Cohen and Co.
Eran@rcspr.co.il
+972-52-440-8020

SOURCE My Size Inc.

Thursday, November 30th, 2017 Uncategorized Comments Off on $MYSZ Will Participate in the International CES Tradeshow

$ESND to Attend 2017 KeyBanc Capital Markets Consumer Conference

DEERFIELD, Ill., Nov. 29, 2017 — Essendant Inc. (NASDAQ:ESND), a leading national wholesale distributor of workplace essentials, today announced that Ric Phillips, president and chief executive officer, and Janet Zelenka, senior vice president and chief financial officer, will host investor meetings at the 2017 KeyBanc Capital Markets Consumer Conference at the InterContinental New York Barclay in New York on Wednesday, December 6, 2017.

An updated investor presentation will be available on the date of the conference on the Investors section of Essendant’s website, on the Presentations page at investors.essendant.com.

About Essendant
Essendant Inc. is a leading supplier of workplace essentials, with 2016 net sales of $5.4 billion. The company stocks a broad assortment of over 190,000 items, including technology products, traditional office products, janitorial and breakroom supplies, office furniture, industrial supplies, and automotive aftermarket tools. The Company’s network of 70 distribution centers enables the Company to ship most products overnight to more than ninety percent of the U.S. For more information, visit www.essendant.com.

Essendant’s common stock trades on the NASDAQ Global Select Market under the symbol ESND.

For Investor Inquiries:
investorrelations@essendant.com
847.627.2900

Wednesday, November 29th, 2017 Uncategorized Comments Off on $ESND to Attend 2017 KeyBanc Capital Markets Consumer Conference

$FTR to Participate in UBS 45th Annual GMCC

NORWALK, Conn.

Frontier Communications Corporation announced today that its Executive Vice President and Chief Financial Officer, Perley McBride, is scheduled to present at the UBS 45th Annual Global Media and Communications Conference in New York, N.Y. on Tuesday, December 5, 2017, at 9:30 A.M. Eastern Time.

A live webcast will be available at Frontier’s Investor Relations website under “Webcasts and Presentations.”

About Frontier Communications

Frontier Communications Corporation (NASDAQ:FTR) is a leader in providing communications services to urban, suburban, and rural communities in 29 states. Frontier offers a variety of services to residential customers over its fiber-optic and copper networks, including video, high-speed Internet, advanced voice, and Frontier Secure® digital protection solutions. Frontier Business offers communications solutions to small, medium, and enterprise businesses. More information about Frontier is available at www.frontier.com.

Frontier Communications
Investors:
Luke Szymczak, 203-614-5044
Vice President, Investor Relations
luke.szymczak@ftr.com
or
Media:
Brigid M. Smith, 203-614-5042
AVP, Corporate Communications
Brigid.smith@ftr.com

Wednesday, November 29th, 2017 Uncategorized Comments Off on $FTR to Participate in UBS 45th Annual GMCC

$CAPR Announces FDA Clearance of IND Application for CAP-1002

Potential Registration Trial in Duchenne Muscular Dystrophy on Track to Initiate in First Quarter of 2018 Company to Host Conference Call and Webcast at 4:30 p.m. ET Today

LOS ANGELES, Nov. 29, 2017 — Capricor Therapeutics (NASDAQ: CAPR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy, a fatal genetic disorder for which there are limited treatment options.

This randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses. The primary efficacy endpoint will be the relative change in the mid-level dimension of the Performance of the Upper Limb test from baseline to Month 12. The HOPE-2 Trial is expected to enroll approximately 84 patients and be conducted at 10-12 U.S. sites.

Capricor believes that if the primary endpoint is reached, the HOPE-2 Trial could serve as a registration trial, meaning that its results could support the submission of a Biologics License Application (BLA) to obtain marketing approval of CAP-1002. Capricor expects to initiate the HOPE-2 Trial in the first quarter of 2018.

Capricor plans to apply for the Regenerative Medicine Advanced Therapy (RMAT) Designation for CAP-1002 based on updated guidance recently issued by the FDA. If granted, the RMAT Designation would be expected to facilitate CAP-1002’s path to potential registration.

The national principal investigator for the HOPE-2 trial will be Craig M. McDonald, M.D., a distinguished thought leader in the clinical management of neuromuscular diseases, including muscular dystrophies, and the development of novel outcome measures for Duchenne muscular dystrophy clinical trials.

“The FDA’s clearance of this IND upon its initial submission is a significant step forward in our development of CAP-1002,” said Linda Marbán, Ph.D., president and chief executive officer. “While there are many clinical initiatives in Duchenne muscular dystrophy, this is one of the very few to focus on non-ambulant patients. These boys and young men are looking to maintain what function they have in their arms and hands and, based on our previous study, we think CAP-1002 may be able to do exactly that.”

Capricor previously reported significant and sustained improvements in cardiac structure and function, as well as skeletal muscle function, following a single dose of intracoronary CAP-1002. The HOPE-2 Trial will test the potential benefit of CAP-1002 as a repeated therapy delivered intravenously, with the goal of providing long-term benefit in a format that is compatible with repeat dosing over time. Support for intravenous infusion, a common mode of drug delivery, is provided by studies which have shown therapeutic benefit in an animal model of Duchenne muscular dystrophy.

Capricor will hold a conference call and slide presentation at 4:30 p.m. ET today to discuss this development. To join: please dial 1-866-652-5200 (domestic) or 1-412-317-6060 (international). Access to the webcast and a replay of the call may be found at http://capricor.com/news/events/.

The HOPE trial was funded in part by the California Institute for Regenerative Medicine.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the age of 30, most commonly from heart failure. It occurs in one in every 3,600 live male births across all races, cultures and countries. Duchenne muscular dystrophy afflicts approximately 200,000 boys and young men around the world. Treatment options are limited, and there is no cure.

About CAP-1002

CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that contains cardiac progenitor cells. CAP-1002 has been shown to exert potent immunomodulatory activity and stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on March 16, 2017, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with the prospectus included therein and prospectus supplements thereto, and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 14, 2017. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. Capricor’s exosomes technology, including CAP-2003, has not yet been approved for clinical investigation.

For more information, please contact:

AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com

Wednesday, November 29th, 2017 Uncategorized Comments Off on $CAPR Announces FDA Clearance of IND Application for CAP-1002

$SLM Employee Everet Zicarelli Named 2017 Emerging Leader

NEWARK, Del.

Zicarelli One of 15 Internal Auditors Worldwide Recognized by Professional Organization

Everet Zicarelli, a member of Sallie Mae’s internal audit team, was honored as a 2017 Emerging Leader by Internal Auditor magazine, a publication produced by the Institute of Internal Auditors (IIA). The publication recognizes up-and-coming internal audit practitioners who are making a difference within their companies, willing to take on new roles and challenges, and mentor younger professionals in the field. Zicarelli was one of only 15 professionals across the globe, all under 30 years old, to be recognized.

“Within Sallie Mae’s internal audit department, we are committed to ensuring our business practices are constantly reviewed and improved to ensure the highest standards for our customers,” said Dan VanSciver, senior vice president and chief audit officer, Sallie Mae. “We also promote continued professional development among our employees, so it’s particularly gratifying to see Everet recognized for his great work.”

Zicarelli joined the internal audit department at Sallie Mae in May 2015 and was promoted to senior internal auditor in March 2016. He is a leader within the company’s on-campus internship recruiting program and is the designated mentor for all internal audit interns. He recently began volunteering at the University of Delaware’s Center for Economic Education and Entrepreneurship Keys to Financial Success program, which prepares K-12 educators and students in economics, personal finance, and entrepreneurship.

Zicarelli is a graduate of the University of Delaware. He received his Certified Internal Auditor (CIA) certification from the Institute of Internal Auditors and was a recipient of their William S. Smith CIA – Certificate of Honors Award for his performance on the CIA examination. He is also a Certified Public Accountant (CPA) licensed in the state of Delaware. In addition to the recognition from the IIA, he recently received a Quarterly Employee Award of Excellence from Sallie Mae.

For more information about saving, planning, and paying for college, visit SallieMae.com.

Sallie Mae (Nasdaq: SLM) is the nation’s saving, planning, and paying for college company. Whether college is a long way off or just around the corner, Sallie Mae offers products that promote responsible personal finance, including private education loans, Upromise rewards, scholarship search, college financial planning tools, and online retail banking. Learn more at SallieMae.com. Commonly known as Sallie Mae, SLM Corporation and its subsidiaries are not sponsored by or agencies of the United States of America.

 

Sallie Mae
Liz Margolis, 302-451-0598
Elizabeth.Margolis@salliemae.com

Wednesday, November 29th, 2017 Uncategorized Comments Off on $SLM Employee Everet Zicarelli Named 2017 Emerging Leader

$LBTYA to Present at the UBS 45th Annual Global Media and Communications Conference

DENVER, Colorado

Liberty Global plc (“Liberty Global”) (NASDAQ: LBTYA, LBTYB, LBTYK, LILA and LILAK) will be presenting at the UBS 45th Annual Global Media and Communications Conference on Wednesday, December 6, 2017 at 12:00 p.m. EST at the Grand Hyatt New York in New York City. Liberty Global CEO Mike Fries will be presenting. Liberty Global may make observations concerning its historical operating performance and outlook. The presentation will be webcast live at www.libertyglobal.com. We intend to archive the webcast under the investor relations section of our website for approximately 30 days.

About Liberty Global

Liberty Global is the world’s largest international TV and broadband company, with operations in more than 30 countries across Europe, Latin America and the Caribbean. We invest in the infrastructure that empowers our customers to make the most of the digital revolution. Our scale and commitment to innovation enable us to develop market-leading products delivered through next-generation networks that connect our over 24 million customers who subscribe to over 50 million television, broadband internet and telephony services. We also serve over 10 million mobile subscribers and offer WiFi service across 10 million access points.

Liberty Global’s businesses are comprised of two stocks: the Liberty Global Group (NASDAQ: LBTYA, LBTYB and LBTYK) for our European operations, and the LiLAC Group (NASDAQ: LILA and LILAK, OTC Link: LILAB), which consists of our operations in Latin America and the Caribbean.

The Liberty Global Group operates in 12 European countries under the consumer brands Virgin Media, Unitymedia, Telenet and UPC. The Liberty Global Group also owns 50% of VodafoneZiggo, a Dutch joint venture, which has 4 million customers, 10 million fixed-line subscribers and 5 million mobile subscribers. The LiLAC Group operates in over 20 countries in Latin America and the Caribbean under the consumer brands VTR, Flow, Liberty, Más Móvil and BTC. In addition, the LiLAC Group operates a sub-sea fiber network throughout the region connecting over 40 markets.

For more information, please visit www.libertyglobal.com.

 

Liberty Global
Investor Relations:
Oskar Nooij, +1 303 220 4218
Christian Fangmann, +49 221 8462 5151
John Rea, +1 303 220 4238
or
Corporate Communications:
Matt Beake, +44 20 8483 6428
Julia Hart, +31 20 778 3345

Wednesday, November 29th, 2017 Uncategorized Comments Off on $LBTYA to Present at the UBS 45th Annual Global Media and Communications Conference

$AMSC Announces $8 Million in D-VAR® System Orders

D-VAR Systems to Support Renewable Connectivity Applications in the U.K. and Industrial Power Quality in the U.S.

DEVENS, Mass., Nov. 29, 2017 — AMSC (NASDAQ:AMSC), a global energy solutions provider serving wind and power grid industry leaders, today announced four new D-VAR® STATCOM system orders valued at over $8 million. Two of the orders serve the renewable energy sector and are expected to be used for connection of wind power plants to the electric grid in the United Kingdom, as well as to provide voltage regulation by responding dynamically to varying load conditions. Two of the orders serve the industrial power quality sector in the United States. Revenue from these four D-VAR® orders is expected to be recognized in fiscal year 2017.

AMSC’s D-VAR interconnection and reactive power compensation solutions are designed to ensure high network performance and stability. The system is a powerful, cost-effective way to provide continuous voltage regulation, improve voltage stability, meet interconnection requirements, and dynamically provide grid support where it is needed.

“We believe that these D-VAR orders represent continued progress toward our objective to grow our Grid revenues year over year,” said Daniel P. McGahn, President and CEO, AMSC. “I am pleased that these orders for industrial applications in the U.S. include two repeat customers in the power quality market.”

Customers utilize AMSC’s D-VAR solutions to provide dynamic voltage control, power factor correction, and post-contingency reactive compensation to stabilize the power grid and prevent undesirable events such as voltage collapse. The D-VAR system is designed to be able to detect and instantaneously compensate for voltage disturbances by dynamically injecting leading or lagging reactive power into the power grid. These solutions are also designed to augment the overall performance of wind farms and to enable developers to meet grid interconnection requirements.

D-VAR reactive compensation systems are classified as Static Compensators, or “STATCOMs,” a member of the FACTS (Flexible AC-Transmission System) family of power electronic solutions for alternating current (AC) power grids.

About AMSC (NASDAQ: AMSC)
AMSC generates the ideas, technologies and solutions that meet the world’s demand for smarter, cleaner … better energy™. Through its Windtec™ Solutions, AMSC provides wind turbine electronic controls and systems, designs and engineering services that reduce the cost of wind energy. Through its Gridtec™ Solutions, AMSC provides the engineering planning services and advanced grid systems that optimize network reliability, efficiency, and performance. AMSC’s solutions are now powering gigawatts of renewable energy globally and are enhancing the performance and reliability of power networks in more than a dozen countries. Founded in 1987, AMSC is headquartered near Boston, Massachusetts with operations in Asia, Australia, Europe, and North America. For more information, please visit www.amsc.com.

AMSC, Windtec, Gridtec, D-VAR, and Smarter, Cleaner … Better Energy are trademarks or registered trademarks of American Superconductor Corporation. All other brand names, product names, trademarks, or service marks belong to their respective holders.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such statements include, but are not limited to, statements about our expectations regarding intended uses of the D-VAR systems; the timing of revenue recognition for the D-VAR systems ordered; and functionality and performance of D-VAR systems; our belief that these D-VAR orders represent continued progress toward achieving our objective to grow our Grid revenues year over year; and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions. Such forward-looking statements represent management’s current expectations and are inherently uncertain. There are a number of important factors that could materially impact the value of our common stock or cause actual results to differ materially from those indicated by such forward-looking statements. These important factors include, but are not limited to: We have a history of operating losses and negative operating cash flows, which may continue in the future and require us additional financing in the future; Our operating results may fluctuate significantly from quarter to quarter and may fall below expectations in any particular fiscal quarter; Our financial condition may have an adverse effect on our customer and supplier relationships; Our success is dependent upon attracting and retaining qualified personnel and our inability to do so could significantly damage our business and prospects; Failure to successfully execute any move of our Devens, Massachusetts manufacturing facility or achieve expected savings following any such move; We rely upon third-party suppliers for the components and sub-assemblies of many of our Wind and Grid products, making us vulnerable to supply shortages and price fluctuations; Our products face intense competition; Many of our revenue opportunities are dependent upon subcontractors and other business collaborators; We may not realize all of the sales expected from our backlog of orders and contracts; We have operations in and depend on sales in emerging markets, and global conditions could negatively affect our operating results or limit our ability to expand our operations outside of these countries; We face risks related to our intellectual property; We face risks related to our legal proceedings; and the important factors discussed under the caption “Risk Factors” in Part 1. Item 1A of our Form 10-K for the fiscal year ended March 31, 2017, and our other reports filed with the SEC. These important factors, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact:
Brion D. Tanous
CleanTech IR, Inc.
Phone: 424-634-8592
Email: Brion.Tanous@amsc.com

Public Relations Contact:
Nicol Golez
Phone: 978-399-8344
Email: Nicol.Golez@amsc.com

Wednesday, November 29th, 2017 Uncategorized Comments Off on $AMSC Announces $8 Million in D-VAR® System Orders

$OESX Expects $1.4M in Revenue from New U.S. Government Retrofit Awards

Annual Energy Savings of Approximately 70% Should Enable Full Recoupment of Installation Costs in a Few Years

MANITOWOC, Wis., Nov. 28, 2017 — Orion Energy Systems, Inc. (NASDAQ:OESX) (Orion Lighting), a leading designer and U.S. manufacturer of high-performance, energy-efficient LED lighting products, announced today the receipt of award notifications to retrofit three U.S. Government facilities with Orion’s LED lighting systems. Orion expects to record at least $1.4 million in revenue from these awards over the balance of its fiscal 2018 year ending March 31, 2018. The bulk of the revenue will be product sales, along with installation services and some engineering and professional services.

Orion is replacing legacy lighting systems at the government facilities with its energy-efficient LED lighting platforms and controls, in support of the customer’s environmental and energy efficiency goals. The customer expects to reduce its annual lighting energy usage by approximately 70%, providing savings that should allow the full recoupment of all project costs in just a few years. The awards follow several projects completed for this government entity over the past few years. Orion anticipates additional retrofit opportunities from this customer in future periods.

Orion CEO, Mike Altschaefl, commented, “We are proud to serve our Country and build upon past work with this valued, long-time U.S. government customer. These awards confirm the strength of our product platform, design, features and value proposition – factors that are resonating with a growing base of new and existing customers.

“Importantly, they also confirm our customer’s confidence in Orion, our commitment to customer satisfaction, and the strong working relationship we have built over several years. Our activity in the government sector continues to be strong, and we are eager to bid on future projects for this customer.”

About Orion Energy Systems
Orion is a leading designer and producer of energy efficient lighting and retrofit lighting solutions for commercial and industrial buildings. Orion manufactures and markets connected lighting systems encompassing LED solid-state lighting and smart controls. Orion systems incorporate patented design elements that deliver significant energy, efficiency, optical and thermal performance that drive financial, environmental, and work-space benefits for a wide variety of customers, including nearly 40% of the Fortune 500.

Twitter:            @OrionLighting and @OrionLightingIR
StockTwits:      @Orion_LED_IR

Investor Relations Contacts:
Bill Hull, CFO
Orion Energy Systems, Inc.
(312) 660-3575 or ir@oesx.com

William Jones; Tanya Kamatu
Catalyst IR
(212) 924-9800 or oesx@catalyst-ir.com

Tuesday, November 28th, 2017 Uncategorized Comments Off on $OESX Expects $1.4M in Revenue from New U.S. Government Retrofit Awards

$CPRX Prices Previously Announced Public Offering of Common Stock

CORAL GABLES, FL–(Nov 28, 2017) – Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) today announced the pricing of its previously announced underwritten public offering. The Company announced that it is selling 14,285,715 shares of its common stock in the public offering at an offering price of $3.50 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of common stock to cover over-allotments, if any. All of the shares in the offering are being sold by Catalyst.

Piper Jaffray & Co. is acting as the lead bookrunner. SunTrust Robinson Humphrey, Inc. is also acting as a bookrunner. H.C. Wainwright & Co. is acting as lead manager and Roth Capital Partners is acting as co-manager for the offering.

Net proceeds from the offering, after underwriting discounts and commissions and other offering expenses, are expected to be approximately $46.6 million. Catalyst plans to use the net proceeds from the offering (i) to fund clinical studies of Firdapse® for the treatment of MuSK-antibody positive Myasthenia Gravis (MuSK-MG) and Spinal Muscular Atrophy (SMA), (ii) to fund pre-commercialization activities for Firdapse®, and (iii) for general corporate purposes. The offering is subject to customary closing conditions and is expected to close on November 30, 2017.

The shares are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-219529) filed pursuant to the Securities Act of 1933, as amended, which was previously filed with, and declared effective by, the Securities and Exchange Commission. A prospectus supplement relating to this offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

When available, copies of the prospectus supplement and the accompanying prospectus relating to these securities will be available on the Investor Relations section of the Company’s website and on the SEC’s website located at http://www.sec.gov. Copies may also be obtained by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by e-mail at prospectus@pjc.com, or by contacting SunTrust Robinson Humphrey, Inc. by mail at 3333 Peachtree Road NE, Atlanta, GA 30326, Attention: Prospectus Department, by telephone at (404) 926-5744, or by e-mail at STRH.Prospectus@suntrust.com.

About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse® is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette’s Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including whether the offering described in this press release will be closed and those other factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2016, the prospectus supplement related to the offering, and Catalyst’s other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC’s website at http://www.sec.gov, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com

Media Contacts
David Schull
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com

Tuesday, November 28th, 2017 Uncategorized Comments Off on $CPRX Prices Previously Announced Public Offering of Common Stock

$ASCMA to Present at Upcoming Conferences

ENGLEWOOD, CO–(Nov 28, 2017) – Ascent Capital Group Inc. (“Ascent” or the “Company”) (NASDAQ: ASCMA) announced today that Mr. Jeffery Gardner, President and Chief Executive Officer of MONI and Mr. Fred Graffam, Senior Vice President and Chief Financial Officer of MONI will participate in the following conferences:

  • Bank of America Leveraged Finance Conference on November 29 and 30, 2017 at the Boca Raton Resort & Club in Boca Raton, FL at 8:50 am ET.
  • Raymond James’ Technology Investors Conference on December 5, 2017 at the Westin New York Grand Central in New York City at 9:00 am ET.
  • Imperial Capital Security Investor Conference on December 7, 2017 at the InterContinental New York Barclay in New York City at 9:00 am ET.

During each conference, management may make observations regarding the financial performance and outlook of both Ascent and MONI.

A live webcast of the Bank of America and Imperial Capital presentations will be made available on Ascent’s Investor Relations website at http://ascentcapitalgroupinc.com/investors.cfm. The Raymond James event will not be webcast.

About Ascent Capital Group, Inc.

Ascent Capital Group, Inc., (NASDAQ: ASCMA) is a holding company that owns 100 percent of its operating subsidiary, MONI, and through MONI, LiveWatch Security, LLC. MONI, headquartered in the Dallas Fort-Worth area, secures more than one million residential customers and commercial client accounts with monitored home and business security system services. MONI is supported by one of the nation’s largest networks of independent Authorized Dealers, providing products and support to customers in the U.S., Canada and Puerto Rico. LiveWatch Security, LLC ®, is a Do-It-Yourself (“DIY”) home security firm, offering professionally monitored security services through a direct-to-consumer sales channel. For more information on Ascent, see http://ascentcapitalgroupinc.com/.

Tuesday, November 28th, 2017 Uncategorized Comments Off on $ASCMA to Present at Upcoming Conferences

$OHGI CEO Mark White Provides Update to Shareholders

LONDON, Nov. 28, 2017 – One Horizon Group, Inc. (NASDAQ:OHGI) issued the following letter to shareholders today from Mark White, Chief Executive Officer.

Dear Fellow Shareholders –

In writing this letter, I would like to begin by sharing my gratitude for each of you and my confidence and pride in the future of One Horizon Group.

I am the first to recognize that in the past few months, our Company has undergone profound change and I want to share with you a few words about my vision for our bright future.

As One Horizon Group’s Founder and CEO, my conviction that we must succeed derives from the responsibility I personally embrace to lead our Company’s strategy to identify, acquire and integrate businesses that will allow us to lead the next wave of cutting edge technologies driving the growth of disruptive social media, on-demand video, gaming, education, security and electronic commerce mobile applications.  We will integrate the target acquisitions with our existing business, streamlining operational efficiencies and increasing profitability.

There are tremendous opportunities within our sights to acquire Asia-based businesses ready to launch their operations globally as well as European and United States-based businesses that are recognized leaders in their respective areas, poised to expand into large markets including China with the international expertise and guidance of our team.

Consumer behavior is shifting at a rapid pace and we are positioned at the intersection of great innovation.  Our shift in strategy is based on significant diligence and we expect to have a front-row seat at the convergence of the physical and digital worlds that will drive unprecedented business opportunities for One Horizon Group.  Although our ambitions may appear grand, we are laser focused on execution and I am confident we will achieve our goals.

As we advance our Company in the marketplace as a forward-thinking technology acquisition business, I recognize that beyond these exciting technologies, platforms and content we will acquire, we must deliver unique value propositions to our customers.  I see a future where our technologies will make lives more exciting, our platforms will be inviting and easy to use, and our content will be unique and desirable.  We have done our homework and we will not be reinventing the wheel; our target acquisitions are already capturing the hearts, minds and finances of significant population groups spanning multiple continents.

For a moment, I would like to talk about people.  It has been said that “leadership is a conversation.”  Many years ago, I learned that by listening to my customers, colleagues and shareholders, I might hear new ideas that could help us improve our Company.  I am proud to be working with a great team including Edwin Lun, Chief Operating Officer, and Martin Ward, Chief Financial Officer.  We plan to regularly communicate with our customers and shareholders.

We will be measured by our innovation, our sales, our profitability, our corporate responsibility, our social impact, and our share price, but we will always maintain our core values.  I am deeply aware that our stock price is an important measure of the progress that we make in the weeks, months and years to come.  The catalyst for this progress will be completing strategic acquisitions that build our capabilities to deliver exponential returns to our shareholders by accelerating the reach of technologies, platforms and content to large numbers of subscribers, users and I expect, raving fans.

While quarterly and annual reports and future updates will quantify our success, I will be taking measure daily so we can anticipate areas of challenge and mobilize our team to take clear and decisive actions that will deliver results.  It is in these details that we will harness the driving force that will take One Horizon Group to the next level.

Thank you all deeply for your support and for joining us on this evolution.

Warm regards,

Mark White
CEO, One Horizon Group, Inc.

About One Horizon Group, Inc.

One Horizon Group, Inc. (NASDAQ:OHGI) is a reseller of secure messaging software for the growing gaming, security and education markets including in China and Hong Kong.  For more information on the Company please visit http://www.onehorizongroup.com/investors-overview/.

Darrow Associates Contacts for OHGI

Bernie Kilkelly
(516) 236-7007
bkilkelly@darrowir.com

Jordan Darrow
(512) 551-9296 
jdarrow@darrowir.com
Tuesday, November 28th, 2017 Uncategorized Comments Off on $OHGI CEO Mark White Provides Update to Shareholders

$VERI Among the First to Be Recognized by AWS for Machine Learning Expertise

COSTA MESA, Calif.

Veritone®, Inc. (NASDAQ: VERI), a leading provider of artificial intelligence (AI) insights and cognitive solutions, today announced that it has achieved Amazon Web Services (AWS) Machine Learning (ML) Competency status. This designation recognizes Veritone for offering solutions that enable prescriptive and predictive capabilities within customer workflows and applications.

AWS ML Competency status designates Veritone as an AWS Partner Network (APN) member that has built solutions that help organizations solve their data challenges, enable machine learning and data science workflows or offer SaaS/API-based capabilities that enhance end applications with machine intelligence. Attaining the AWS ML Competency demonstrates to Veritone’s customers that the company has ML expertise on AWS.

“Achieving AWS ML Competency status recognizes Veritone’s proven track record of making AI accessible and actionable to institutions and organizations by combining the most advanced processing engines across major cognitive functions with a suite of powerful applications and a proprietary orchestration layer informed by machine learning,” said Chad Steelberg, chairman and chief executive officer of Veritone. “Our team is dedicated to helping customers achieve their business goals by uncovering previously-unavailable intelligence and by leveraging the agility of AWS.”

AWS is enabling scalable, flexible, and cost-effective solutions for startups to global enterprises. To support the seamless integration and deployment of these solutions, AWS established the AWS Partner Competency Program to help customers identify Consulting and Technology APN Partners with deep industry experience and expertise.

“Given the complexity of building a scalable and reliable production workflow that serves billions of predictions, deploying machine learning at scale is still a challenge,” said Joseph Spisak, global lead for artificial intelligence and machine learning partnerships, Amazon Web Services, Inc. “We are thrilled to have Veritone join us as an APN Partner for the Artificial Intelligence and Machine Learning Competency Program. By automating routine tasks, teams are able focus squarely on the problems they are trying to solve and spend less time worrying about how to optimize and deploy their models.”

The first commercially-available AI operating system, the Veritone aiWARE™ platform is available on AWS Marketplace. As an APN Advanced Technology Partner in the AWS Partner Network (APN), Veritone provides AWS customers with full access to aiWARE, enabling the index and search of unstructured data to derive actionable business insights.

About Veritone

Veritone (NASDAQ: VERI) is a leading artificial intelligence company that has developed a unique platform, aiWARE, which unlocks the power of AI-based cognitive computing to transform and analyze unstructured public and private audio and video data for clients in a variety of markets, including media, politics, legal and government. The open platform integrates an ecosystem of best-of-breed cognitive engines and powerful applications, which can be orchestrated together to reveal valuable, multivariate insights. aiWARE delivers unprecedented insights by unlocking data from linear files such as radio and TV broadcasts, surveillance footage and public and private content globally. To learn more about Veritone, please visit Veritone.com.

Safe Harbor Statement

This news release contains forward-looking statements, including without limitation statements regarding Veritone’s listing on the AWS Marketplace, its status as an Advanced Technology Partner in the AWS Partner Network, the recognition of its artificial intelligence / machine learning competency, and the use of the Veritone aiWARE platform by AWS users and the expected benefits. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Assumptions relating to the foregoing involve judgments and risks with respect to various matters which are difficult or impossible to predict accurately and many of which are beyond the control of Veritone. Certain of such judgments and risks are discussed in Veritone’s SEC filings. Although Veritone believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by Veritone or any other person that their objectives or plans will be achieved. Veritone undertakes no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 

BLASTmedia for Veritone, Inc.
Meghan Matheny, 317-806-1900 x115
meghan_matheny@blastmedia.com

Tuesday, November 28th, 2017 Uncategorized Comments Off on $VERI Among the First to Be Recognized by AWS for Machine Learning Expertise

$ZN Receives Multi-Year Extension on Megiddo-Jezreel License

Zion Prepares to Resume Drilling Operations

DALLAS and CAESAREA, Israel, Nov. 27, 2017 — Zion Oil & Gas, Inc. (NASDAQ: ZN) is pleased to announce that on November 20th, 2017 Zion received a two-year extension on its Megiddo-Jezreel License No. 401, extending its validity to December 2, 2019.  Zion’s CEO, Victor Carrillo, expresses his optimism, “During this season of thanksgiving, we are especially grateful that Israel’s Petroleum Commissioner has granted Zion a multi-year extension that validates the years of work and accomplishments on the license. This multi-year extension should assure investors that our current well will continue unabated, without the risk that the Energy Ministry would ‘pull our license.’ Since I joined the company in 2011, I’ve seen no multi-year license extensions, as any extension is typically only one year at a time.  Zion’s proven track record of continued exploration in Israel, and our history of fulfilling our obligations to the State of Israel, give confidence to the current Petroleum Commissioner to grant us this multi-year license extension.”

Zion’s President, Dustin Guinn, says, “We have received on location most of the equipment that was ordered to allow us to prepare to resume drilling operations soon.  While it has been a patience-testing delay, I would like to reiterate that it was one that was necessary to maintain the integrity of the wellbore which will allow Zion to safely continue drilling deeper.  I am very excited about resuming drilling operations.  We have begun rigging up the equipment that has arrived on location and once all are inspected and tested we will run back in the hole and resume drilling.  As we approach what I believe is the most exciting section of the well, we ask that you continue to pray for safe operations throughout the drilling and testing of the well.”

Click Here to Learn More About Unit Program

FORWARD-LOOKING STATEMENTS: Statements in this communication that are not historical fact, including statements regarding Zion’s planned operations, geophysical and geological data and interpretation, anticipated attributes of geological strata being drilled, the presence or recoverability of hydrocarbons, operational risks in testing and well completion, the sufficiency of cash reserves, ability to raise additional capital, timing and potential results thereof and plans contingent thereon are forward-looking statements as defined in the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions that are subject to significant known and unknown risks, uncertainties and other unpredictable factors, many of which are described in Zion’s periodic reports filed with the SEC and are beyond Zion’s control. These risks could cause Zion’s actual performance to differ materially from the results predicted by these forward-looking statements. Zion can give no assurance that the expectations reflected in these statements will prove to be correct and assumes no responsibility to update these statements.

Contact Info:
Zion Oil & Gas, Inc. (NASDAQ: ZN)
12655 North Central Expressway, Suite 1000, Dallas, TX 75243
Andrew Summey
Telephone: 888-891-9466
Email: andrew.summey@zionoil.com
www.zionoil.com

Monday, November 27th, 2017 Uncategorized Comments Off on $ZN Receives Multi-Year Extension on Megiddo-Jezreel License

$MTBC Announces Signing of Its Largest Client, a 950 Provider Group

SOMERSET, N.J., Nov. 27, 2017 — MTBC (NASDAQ:MTBC) (NASDAQ: MTBCP), a leading provider of mHealth and cloud-based clinical and practice management solutions, today announced the signing of a 950 provider multi-state therapy group, which is expected to ramp-up by the end of 2017 to become the client generating MTBC’s largest monthly revenue.

“We’re honored that one of the nation’s largest and most innovative clinician-owned providers of physical, occupational and speech therapy services has selected MTBC,” said Karl Johnson, MTBC SVP Sales and Marketing. “With their unique practice emphasis, and exceptional rate of sustained growth, they’ll be leveraging our integrated solution to support continued growth and scale.”

“We will begin providing services to our new client this month and expect to be generating initial revenue during fourth quarter 2017,” said Stephen Snyder, MTBC President.  “As we begin 2018, this new relationship will likely represent our largest single source of monthly client revenue.”

Under the service agreement entered into by the parties on November 21st, MTBC will be providing revenue cycle management services and personnel support.  MTBC will also be making available its industry leading platform and practice management solution.

About MTBC

MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers throughout the United States. Our integrated Software-as-a-Service (SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC’s common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”

For additional information, please visit our website at www.mtbc.com.

Follow MTBC on TWITTER, LINKEDIN and FACEBOOK.

Forward-Looking Statements
This press release contains various forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “goals”, “intend”, “likely”, “may”, “plan”, “potential”, “predict”, “project”, “will” or the negative of these terms or other similar terms and phrases.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the ramp-up, revenue and retention of new and existing clients, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, but are not limited to, the company’s ability to manage growth; integrate acquisitions; effectively transition, ramp-up, and retain new and existing customers; comply with controlling contractual obligations and legal requirements; and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Although we believe that the expectations reflected in the forward-looking statements contained in this press release are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE MTBC

Company and Investor Contact:
Bill Korn
Chief Financial Officer
Medical Transcription Billing, Corp. 
bkorn@mtbc.com 
(732) 873-5133
Monday, November 27th, 2017 Uncategorized Comments Off on $MTBC Announces Signing of Its Largest Client, a 950 Provider Group

$NEPT Extends Global MaxSimil® Licence To Cannabis-Derived Products

LAVAL, QUÉBEC–(Nov. 27, 2017) – Neptune Technologies & Bioressources Inc. (“Neptune Wellness” or the “Company”) (NASDAQ:NEPT)(TSX:NEPT), today announced an exclusive, worldwide and royalty bearing licensing agreement for the use of the MaxSimil® technology, a patented omega-3 fatty acid delivery technology and strong growth driver of Neptune’s Solutions business, in combination with cannabis-derived products.

This new agreement allows Neptune to research, manufacture, formulate, distribute and sell monoglyceride omega-3-rich ingredients in combination with cannabis and/or cannabinoid-rich hemp-derived ingredients for medical and adult use applications.

As indicated in the past, the Company believes the MaxSimil® technology has the ability to enhance absorption of lipid-based and lipid soluble ingredients such as cannabinoids, essential fatty acids including EPA and DHA omega-3s, vitamins A, D, K and E, CoQ10 and others. This could be especially beneficial in increasing the absorption of ingredients which are not easily absorbed, such as cannabidiol (CBD).

“Neptune’s strategy is to position itself in segments characterized by size and growth and the legal cannabis industry fits well with this and our wellness mission. Our core competencies in science, regulatory affairs, formulation, commercialization and oil extraction are tremendous foundations to position ourselves for success. Over the past year, MaxSimil® has been a proven winner in our Solutions Business and we are excited to apply this technology to cannabis-derived products. We will now begin investigating the impact of this innovative technology on the absorption and benefits of cannabis and cannabinoid ingredients,” said Jim Hamilton, President & CEO of Neptune.

The Company submitted a written application to Health Canada to produce cannabis oil under the Access to Cannabis for Medical Purposes Regulations (ACMPR), which at this time has been confirmed by the agency as being at the Review and Security Clearance stage (stage 2 of 6).

About Neptune Technologies & Bioressources Inc.

Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company develops turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions in high potential growth segments such as in the medical cannabis field.

Neptune is also pursuing opportunities in the prescription drug markets, through its 34% owned subsidiary Acasti Pharma Inc. (“Acasti”). Acasti focuses on the research, development and commercialization of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.

The Company’s head office is located in Laval, Quebec.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking information in this press release includes, but is not limited to, information or statements about our ability to successfully develop, produce, supply, promote or generate any revenue from the sale of any cannabis-based products for medical use, as well as the results of any clinical trials associated thereto.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Information” section contained in Neptune’s latest Annual Information Form (the “AIF”), which also forms part of Neptune’s latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune’s website at www.neptunebiotech.com. All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under “Risk Factors”.

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

Neptune Wellness Solutions
Mario Paradis
VP & CFO, Neptune
m.paradis@neptunecorp.com
1.450.687.2262 x236

Investor Relations Contact
(Canada)
Pierre Boucher
MaisonBrison
1.514.731.0000
pierre@maisonbrison.com

Investor Relations Contact
(U.S.)
Ed McGregor/Jody Burfening
LHA, IR
1.212.838.3777
emcgregor@lhai.com

Monday, November 27th, 2017 Uncategorized Comments Off on $NEPT Extends Global MaxSimil® Licence To Cannabis-Derived Products